Park and colleagues (26) reported that mutations of TP53 at baseline were associated with shorter PFS in a cohort of patients treated with palbociclib plus ET in matched pretreatment tumor biopsies, on-treatment tissues, and progression tissues and also integrated HRD features to demonstrate shorter PFS. The gene discussed is TP53; the disease is neoplasm.